EV Biologics, Inc. (YECO)
USD 0.09
(-0.12%)
USD 0.09
(-0.12%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -483.06 Thousand USD | 18.13% |
| 2022 | -590.04 Thousand USD | -2332.15% |
| 2021 | -24.26 Thousand USD | 75.49% |
| 2020 | -98.96 Thousand USD | -0.57% |
| 2019 | -98.4 Thousand USD | 0.0% |
| 2017 | 52.39 Thousand USD | -98.41% |
| 2016 | 3.28 Million USD | -74.42% |
| 2015 | 12.85 Million USD | -15.5% |
| 2014 | 15.21 Million USD | 7.8% |
| 2013 | 14.11 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 85.42 Thousand USD | 144.6% |
| 2024 Q2 | -191.55 Thousand USD | -1610.27% |
| 2024 Q1 | -11.2 Thousand USD | 97.02% |
| 2023 FY | -483.06 Thousand USD | 18.13% |
| 2023 Q2 | -84.46 Thousand USD | -8.77% |
| 2023 Q4 | -375.8 Thousand USD | -74.06% |
| 2023 Q3 | -215.9 Thousand USD | -155.62% |
| 2023 Q1 | -77.65 Thousand USD | 85.17% |
| 2022 Q3 | -8960.00 USD | 74.01% |
| 2022 FY | -590.04 Thousand USD | -2332.15% |
| 2022 Q2 | -34.48 Thousand USD | 0.0% |
| 2022 Q4 | -523.49 Thousand USD | -5742.62% |
| 2021 Q2 | - USD | 100.0% |
| 2021 FY | -24.26 Thousand USD | 75.49% |
| 2021 Q3 | - USD | 0.0% |
| 2021 Q1 | -157.3 Thousand USD | 0.0% |
| 2020 FY | -98.96 Thousand USD | -0.57% |
| 2019 FY | -98.4 Thousand USD | 0.0% |
| 2017 FY | 52.39 Thousand USD | -98.41% |
| 2017 Q4 | -92.67 Million USD | 0.0% |
| 2017 Q2 | -466.2 Thousand USD | 0.0% |
| 2017 Q1 | -466.2 Thousand USD | 75.75% |
| 2016 FY | 3.28 Million USD | -74.42% |
| 2016 Q4 | -1.92 Million USD | -78.78% |
| 2016 Q3 | -1.07 Million USD | 86.91% |
| 2016 Q2 | -8.21 Million USD | -331.0% |
| 2016 Q1 | 3.55 Million USD | 7.09% |
| 2015 Q1 | 3.03 Million USD | 1.69% |
| 2015 Q4 | 3.31 Million USD | -26.59% |
| 2015 Q3 | 4.52 Million USD | 28.97% |
| 2015 FY | 12.85 Million USD | -15.5% |
| 2015 Q2 | 3.5 Million USD | 15.51% |
| 2014 Q4 | 2.98 Million USD | -10.38% |
| 2014 Q1 | 3.59 Million USD | 2.87% |
| 2014 Q2 | 4.42 Million USD | 22.84% |
| 2014 Q3 | 3.33 Million USD | -24.65% |
| 2014 FY | 15.21 Million USD | 7.8% |
| 2013 Q2 | 3.32 Million USD | 4.9% |
| 2013 Q1 | 3.16 Million USD | -17.01% |
| 2013 Q3 | 3.69 Million USD | 11.38% |
| 2013 FY | 14.11 Million USD | 0.0% |
| 2013 Q4 | 3.49 Million USD | -5.42% |
| 2012 Q4 | 3.81 Million USD | 99899.97% |
| 2012 Q3 | 3814.60 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 63.827% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 90.424% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 97.293% |
| Nascent Biotech, Inc. | -2.22 Million USD | 78.337% |
| Rebus Holdings, Inc. | -664 Thousand USD | 27.25% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 100.59% |
| Qrons Inc. | -643.67 Thousand USD | 24.953% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -23.999% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 99.13% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -16.266% |
| Skye Bioscience, Inc. | -13.67 Million USD | 96.467% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 99.327% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 109.829% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -84.568% |
| SQZ Biotechnologies Company | -75.82 Million USD | 99.363% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 83.053% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 68.552% |
| Mesoblast Limited | -84.14 Million USD | 99.426% |
| Marizyme, Inc. | -34.08 Million USD | 98.583% |
| Genus plc | 6.4 Million USD | 107.548% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 104.958% |
| Pharming Group N.V. | -4.87 Million USD | 90.1% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 75.683% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 48.135% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 94.215% |
| ContraFect Corporation | -56.88 Million USD | 99.151% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 89.394% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 65.545% |
| IMV Inc. | -38.67 Million USD | 98.751% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 82.439% |
| MultiCell Technologies, Inc. | -722.81 USD | -66731.117% |
| ONE Bio Corp. | 13.68 Million USD | 103.531% |
| Accustem Sciences Inc. | -3.74 Million USD | 87.106% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 99.181% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Q BioMed Inc. | -3.44 Million USD | 85.98% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 113.646% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 81.615% |
| Biomind Labs Inc. | -1 Million USD | 52.153% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 99.121% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 83.35% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 92.734% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 74.09% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1512.787% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 96.956% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 75.005% |
| GB Sciences, Inc. | -1.42 Million USD | 65.994% |
| Alpha Cognition Inc. | -9.7 Million USD | 95.023% |
| HST Global, Inc. | -140.9 Thousand USD | -242.823% |
| CSL Limited | 3.7 Billion USD | 100.013% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 57.058% |
| Halberd Corporation | -75.05 Thousand USD | -543.654% |
| Enzolytics Inc. | -2.14 Million USD | 77.519% |
| Agentix Corp. | -1.37 Million USD | 64.785% |
| Resverlogix Corp. | -12.74 Million USD | 96.211% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 84.753% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.886% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 53.73% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 83.454% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 69.414% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 85.813% |
| AVAX Technologies, Inc. | 6.69 Million USD | 107.218% |
| Zenith Capital Corp. | -8.94 Million USD | 94.598% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.884% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2672.872% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 80.326% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -181.653% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 75.904% |
| Kadimastem Ltd | -3.04 Million USD | 84.111% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 50.911% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 61.54% |
| BioStem Technologies, Inc. | -7.77 Million USD | 93.79% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -166.172% |
| LadRx Corporation | -3.82 Million USD | 87.366% |
| Cell Source, Inc. | -4.32 Million USD | 88.832% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 29.68% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 29.68% |
| NovAccess Global Inc. | -2.46 Million USD | 80.417% |
| Affymax, Inc. | -15.04 Million USD | 96.789% |
| Itoco Inc. | -919.14 Thousand USD | 47.444% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 88.603% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 56.831% |
| Mobile Lads Corp. | -554.55 Thousand USD | 12.891% |
| CytoDyn Inc. | -18.05 Million USD | 97.325% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1819.197% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -119.496% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 14.46% |
| SYBLEU INC | -149.18 Thousand USD | -223.812% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 73.404% |
| International Stem Cell Corporation | -663 Thousand USD | 27.14% |
| Bioxytran, Inc. | -3.82 Million USD | 87.355% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -817.671% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -2274.936% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 98.668% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 70.144% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 34.352% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 84.472% |
| Neutra Corp. | -229.48 Thousand USD | -110.497% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 97.246% |
| PureTech Health plc | -146.19 Million USD | 99.67% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 97.752% |
| IXICO plc | -1.43 Million USD | 66.384% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 94.91% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 99.603% |
| CSL Limited | 3.81 Billion USD | 100.013% |
| Cellectis S.A. | -108.85 Million USD | 99.556% |